Crohn's Disease

Use of a universal nutritional screening tool may help identify patients with inflammatory bowel disease who are at high risk for malnutrition and other adverse outcomes, according to data presented at the ACG Annual Scientific Meeting.

Among patients with inflammatory bowel disease, the effectiveness of the COVID-19 vaccine was similar when compared to controls without the disease, according to study results.

Early anti-tumor necrosis factor administration reduced late B2 development among pediatric patients with Crohn’s disease, according to a presenter.

A point-of-care intestinal ultrasound effectively assessed endoscopic disease severity through bowel wall thickness, according to a poster presentation.

In this Healio Gastroenterology video exclusive, Miguel Regueiro, MD, FACG, discussed how anti-TNF therapy should be used as first-line therapy for treatment of inflammatory bowel disease.

In this Healio Gastroenterology video exclusive, Stephen B. Hanauer, MD, FACG, discussed intravenous iron products being used in the treatment iron deficiency anemia in patients with inflammatory bowel disease.

The Crohn’s disease exclusion diet with or without enteral nutrition induced and maintained remission in adult patients with mild to moderate CD and may lead to full endoscopic remission.

In a video exclusive, Jan Wehkamp, MD, vice president, gastroenterology global disease area leader at Janssen Pharmaceuticals, reported positive long-term data evaluating Tremfya for the treatment of patients with Crohn’s disease.

Immunocompromised individuals have several justifiable concerns surrounding COVID-19. One of those concerns is that a two-dose vaccine schedule may not produce a sufficient antibody response to protect them from the virus.

Using a novel clinical pathway integrated into the electronic medical record, researchers were able to identify patients with inflammatory bowel disease who were overdue for medical follow-ups, according to data presented at the ACG Annual Scientific Meeting.